semaglutide shortage ending What's New in Obesity Treatment? Semaglutide Shortage Ends: Compounded Versions

These DEGs were demonstrated on Venn diagrams and volcano plots

Insulin response gets better in most users on either drug, enabling their bodies to deal with blood sugar with less exertion

Glucagon-like peptide-1 (GLP-1), Glucose-dependent insulinotropic polypeptide (GIP) Glucagon (GCG)

Most events were mild to moderate, decreased over time with repeat use, and did not lead to discontinuation in most participants

Current guidelines do not recommend combination therapy with GLP-1 RAs and DPP-4 inhibitors, and the ADA/EASD consensus report specifically recommends discontinuation of DPP-4 inhibitors when initiating GLP-1 RA therapy